ANGPTL4 and colorectal cancer: Notably, the consistency of findings across drug-target Mendelian randomization and conventional epidemiological analysis using independent cohort studies, both of which may be susceptible to unrelated sources of bias, permitted us to increase confidence in our conclusions relating circulating ANGPTL4 to colorectal cancer risk.77